ARGENX SE's ticker is ARGX and the CUSIP is 04016X101. A total of 335 filers reported holding ARGENX SE in Q3 2023. The put-call ratio across all filers is 0.33 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $91 | -98.7% | 625 | -58.3% | 0.01% | – |
| Q3 2022 | $7,000 | -84.8% | 1,500 | 0.0% | 0.00% | -100.0% |
| Q2 2022 | $46,000 | -87.2% | 1,500 | +15.4% | 0.00% | -83.3% |
| Q1 2021 | $358,000 | +11.5% | 1,300 | -35.0% | 0.02% | +20.0% |
| Q4 2020 | $321,000 | +66.3% | 2,000 | -55.4% | 0.02% | +25.0% |
| Q3 2020 | $193,000 | -65.5% | 4,480 | -74.6% | 0.01% | -67.6% |
| Q2 2020 | $559,000 | +119.2% | 17,629 | +71.2% | 0.04% | +184.6% |
| Q1 2020 | $255,000 | -61.9% | 10,300 | -31.3% | 0.01% | -67.5% |
| Q4 2019 | $670,000 | +980.6% | 15,000 | +294.7% | 0.04% | +566.7% |
| Q3 2019 | $62,000 | -20.5% | 3,800 | -58.7% | 0.01% | -14.3% |
| Q2 2019 | $78,000 | +1850.0% | 9,200 | +607.7% | 0.01% | – |
| Q1 2019 | $4,000 | -76.5% | 1,300 | -31.6% | 0.00% | -100.0% |
| Q4 2018 | $17,000 | -71.7% | 1,900 | +7.7% | 0.00% | -50.0% |
| Q3 2018 | $60,000 | – | 1,764 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 297,701 | $112,778,070 | 70.21% |
| Artia Global Partners LP | 85,204 | $32,277,831 | 12.30% |
| Avoro Capital Advisors LLC | 1,265,555 | $479,430,201 | 7.16% |
| DCF Advisers, LLC | 25,000 | $9,470,750 | 6.40% |
| Eagle Health Investments LP | 60,300 | $22,843,449 | 5.27% |
| Avidity Partners Management LP | 625,000 | $236,768,750 | 5.13% |
| Bellevue Group AG | 911,100 | $345,152,013 | 4.58% |
| Fairmount Funds Management LLC | 73,526 | $27,853,855 | 4.42% |
| Paradigm Biocapital Advisors LP | 89,556 | $33,926,499 | 3.98% |
| RTW INVESTMENTS, LP | 482,195 | $182,669,932 | 3.73% |